1.56

3.31% 0.05

After Hours: 1.56

Compass Therapeutics Inc (CMPX)

Overview News Price History Financials Discussions Forecast

Compass Therapeutics Inc stock is traded at $1.56, with a volume of 679.64K. It is up +3.31% in the last 24 hours and down -9.30% over the past month. Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Previous Close:

$1.51

Open:

$1.54

24h Volume:

679.64K

Relative Volume:

1.38

Market Cap:

$207.76M

Revenue:

Net Income/Loss:

$-45.44M

P/E Ratio:

-4.2162

EPS:

-0.37

Net Cash Flow:

$-42.28M

1W Performance:

+13.87%

1M Performance:

-9.30%

6M Performance:

+6.12%

1Y Performance:

-4.88%

1-Day Range:

$1.525

$1.64

1-Week Range:

$1.34

$1.64

52-Week Range:

$0.765

$2.34

Compass Therapeutics Inc Stock (CMPX) Company Profile

Name

Compass Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

617-500-8099

Address

80 GUEST STREET, BOSTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CMPX's Discussions on Twitter

Compare CMPX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CMPX Compass Therapeutics Inc	1.56	207.76M	0	-45.44M	-42.28M	-0.37
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-15-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-31-23	Initiated	Jefferies	Buy
Jan-27-23	Initiated	Stifel	Buy
May-23-22	Resumed	H.C. Wainwright	Buy
Mar-15-22	Initiated	Ladenburg Thalmann	Buy
Jan-19-22	Initiated	B. Riley Securities	Buy
Dec-22-21	Initiated	Raymond James	Outperform
Dec-20-21	Initiated	SVB Leerink	Outperform
Dec-15-21	Initiated	Wedbush	Outperform

View All

Compass Therapeutics Inc Stock (CMPX) Latest News

Nov 25, 2024

Major Depressive Disorder Market to Register Immense Growth by 2034 Owing to a Robust Pipeline | DelveInsight - PR Newswire UK

Nov 25, 2024

Nov 22, 2024

Layoff Tracker: Sonata Therapeutics Laying Off 20 Employees, Changing Leadership - BioSpace

Nov 22, 2024

Nov 21, 2024

Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX) - Yahoo Canada Finance

Nov 21, 2024

Nov 19, 2024

PD-1 and PD-L1 Inhibitors Market Future Trends and Scope Analysis Report - openPR

Nov 19, 2024

Nov 18, 2024

FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World

Nov 18, 2024

Compass Therapeutics (NASDAQ:CMPX) Cut to Market Perform at Leerink Partners - Defense World

Nov 18, 2024

Nov 17, 2024

Leerink Partnrs Downgrades Compass Therapeutics (NASDAQ:CMPX) to Hold - MarketBeat

Nov 16, 2024

Nov 15, 2024

DelphX announces non-brokered unit private placement - MSN

Nov 15, 2024

U.S. STOCKS FuelCell Energy, consumer goods stocks, Rocket Companies - XM

Nov 15, 2024

Compass Therapeutics (NASDAQ:CMPX) Downgraded to "Market Perform" Rating by Leerink Partners - MarketBeat

Nov 15, 2024

Wedbush Expects Higher Earnings for Compass Therapeutics - MarketBeat

Nov 15, 2024

What is HC Wainwright's Forecast for CMPX FY2024 Earnings? - MarketBeat

Nov 15, 2024

Nov 14, 2024